{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:00:54Z","timestamp":1792814454254,"version":"4.5.0"},"reference-count":48,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0393","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T12:34:47Z","timestamp":1528115687000},"source":"Crossref","is-referenced-by-count":25,"title":["Frequent Adverse Drug Reactions, and Medication Groups under Suspicion"],"prefix":"10.3238","author":[{"given":"Diana","family":"Dubrall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ale\u0161ik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Paeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"10.3238\/arztebl.2018.0393_ref1","doi-asserted-by":"crossref","unstructured":"Coloma PM, Trifir\u00f2 G, Patadia V, Sturkenboom M: Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf 2013; 36: 183\u201397","DOI":"10.1007\/s40264-013-0018-x"},{"key":"10.3238\/arztebl.2018.0393_ref2","doi-asserted-by":"crossref","unstructured":"Paludetto MN, Olivier-Abbal P, Montastruc JL: Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France? Pharmacoepidemiol Drug Saf 2012; 21: 1289\u201394","DOI":"10.1002\/pds.3333"},{"key":"10.3238\/arztebl.2018.0393_ref3","doi-asserted-by":"crossref","unstructured":"Huang YL, Moon J, Segal JB: A comparison of active adverse event surveillance systems worldwide. Drug Saf 2014; 37: 581\u201396","DOI":"10.1007\/s40264-014-0194-3"},{"key":"10.3238\/arztebl.2018.0393_ref4","doi-asserted-by":"crossref","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM: The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf 2014; 37: 283\u201394","DOI":"10.1007\/s40264-014-0150-2"},{"key":"10.3238\/arztebl.2018.0393_ref5","doi-asserted-by":"crossref","unstructured":"Amery WK: Why there is a need for pharmacovigilance. Pharmacoepidemiol Drug Saf 1999; 8: 61\u20134","DOI":"10.1002\/(SICI)1099-1557(199901\/02)8:1<61::AID-PDS395>3.0.CO;2-A"},{"key":"10.3238\/arztebl.2018.0393_ref6","doi-asserted-by":"crossref","unstructured":"Pacurariu AC, Coloma PM, van Haren A, Genov G, Sturkenboom MC, Straus SM: A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee. Drug Saf 2014; 37: 1059\u201366","DOI":"10.1007\/s40264-014-0240-1"},{"key":"10.3238\/arztebl.2018.0393_ref7","doi-asserted-by":"crossref","unstructured":"Harpaz R, DuMochel W, Shah NH: Big data and adverse drug reaction detection. Clin Pharmacol & Ther 2016; 99: 268\u201370","DOI":"10.1002\/cpt.302"},{"key":"10.3238\/arztebl.2018.0393_ref8","doi-asserted-by":"crossref","unstructured":"Pacurariu AC, Straus SM, Trifir\u00f2 G, et al.: Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection. Drug Saf 2015; 38: 1201\u201310","DOI":"10.1007\/s40264-015-0341-5"},{"key":"10.3238\/arztebl.2018.0393_ref9","doi-asserted-by":"crossref","unstructured":"Robb MA, Racoosin JA, Sherman RE, et al.: The US Food and Drug Administration\u2018s Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf 2012; 21: 9\u201311","DOI":"10.1002\/pds.2311"},{"key":"10.3238\/arztebl.2018.0393_ref10","unstructured":"European Medicines Agency: Guideline on good pharmacovigilance practices (GVP). Module IX \u2014 signal management (Rev 1). www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2017\/10\/WC500236408.pdf (last accessed on 9 October 2017)."},{"key":"10.3238\/arztebl.2018.0393_ref11","unstructured":"Arzneimittelgesetz: Gesetz \u00fcber den Verkehr mit Arzneimitteln (Arzneimittelgesetz \u2013 AMG). Arzneimittelgesetz in der Fassung der Bekanntmachung vom 12. Dezember 2005 (BGBl. I S. 3394), zuletzt ge\u00e4ndert durch Artikel 5 des GKV-Arzneimittelversorgungsst\u00e4rkungsgesetzes (AMVSG) vom 4. Mai 2017 (BGBl. I S. 1050)."},{"key":"10.3238\/arztebl.2018.0393_ref12","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM): Nebenwirkungsmeldung durch Angeh\u00f6rige der Heilberufe. www.bfarm.de\/SharedDocs\/Formulare\/DE\/Arzneimittel\/Pharmakovigilanz\/aa-uaw-melde-bogen.pdf?__blob=publicationFile&v=17."},{"key":"10.3238\/arztebl.2018.0393_ref13","unstructured":"Paul-Ehrlich-Institut (PEI): Meldung von Verdachtsf\u00e4llen unerw\u00fcnschter Arzneimittelwirkungen und Impfkomplikationen. www.pei.de\/DE\/infos\/fachkreise\/meldeformulare-fach\/meldeformulare-fach-node.html (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref14","unstructured":"Stammschulte T, Pachl H, Gundert-Remy U, et al.: Einf\u00fchrung in die Grundlagen der Pharmakovigilanz (Teil II): Spontanmeldesystem zur Erfassung von Verdachtsf\u00e4llen unerw\u00fcnschter Arzneimittelwirkungen (UAW). Bulletin zur Arzneimittelsicherheit 2010; 4: 18\u201326."},{"key":"10.3238\/arztebl.2018.0393_ref15","unstructured":"Bundes\u00e4rztekammer: (Muster-)Berufsordnung f\u00fcr die in Deutschland t\u00e4tigen \u00c4rztinnen und \u00c4rzte \u2013 MBO-\u00c4 1997 \u2013 in der Fassung des Beschlusses des 118. Deutschen \u00c4rztetages 2015 in Frankfurt am Main, Stand: 27.05.2015."},{"key":"10.3238\/arztebl.2018.0393_ref16","unstructured":"European Medicines Agency: EudraVigilance. www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000679.jsp&mid=WC0b01ac05800250b5 (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref17","unstructured":"EudraVigilance. H\u00e4ufig gestellte Fragen rund um das Meldesystem. www.adrreports.eu\/de\/faqs.html (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref18","unstructured":"Deutsches Institut f\u00fcr Medizinische Dokumentation und Information (DIMDI): Anatomisch-Therapeutisch-Chemische (ATC) Klassifikation. www.dimdi.de\/static\/de\/amg\/atcddd\/index.htm (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref19","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: Anatomisch-Therapeutisch-Chemische (ATC) Klassifikation. www.whocc.no\/atc_ddd_index\/ (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref20","unstructured":"MedDRA: Medical Dictionary for Regulatory Activities. www.meddra.org\/how-to-use\/support-documentation (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref21","unstructured":"European Medicines Agency: Guideline on good pharmacovigilance practices (GVP). Module VI \u2014 Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2017\/08\/WC500232767.pdf (last accessed on 28 July 2017)."},{"key":"10.3238\/arztebl.2018.0393_ref22","unstructured":"Statistisches Bundesamt: Bev\u00f6lkerungsstand. www.destatis.de\/DE\/ZahlenFakten\/GesellschaftStaat\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen_\/lrbev03.html (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref23","doi-asserted-by":"crossref","unstructured":"Schwabe U, Ludwig WD: Arzneiverordnungen 2016 im \u00dcberblick. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J (eds.): Arzneiverordnungsreport 2017. Berlin, Heidelberg: Springer 2017; 3\u201332","DOI":"10.1007\/978-3-662-54630-7_1"},{"key":"10.3238\/arztebl.2018.0393_ref24","unstructured":"Bundes\u00e4rztekammer: \u00c4rztestatistik zum 31. Dezember 2016. www.bundesaerztekammer.de\/fileadmin\/user_upload\/downloads\/pdf-Ordner\/Statistik2016\/Stat16AbbTab.pdf (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref25","unstructured":"Einf\u00fchrung der Meldepflicht 1987 und Bekanntmachung dazu vom 28.10.1987. Anzeige von Nebenwirkungen, Wechselwirkungen mit anderen Arzneimitteln und Arzneimittelmissbrauch nach \u00a72 Abs. Satz 2 AMG vom 28.10.1987."},{"key":"10.3238\/arztebl.2018.0393_ref26","unstructured":"Gemeinsame Bekanntmachung \u00fcber die zu verwendenden Standards\u00e4tze in der Fachinformation und Packungsbeilage zum Berichten von Nebenwirkungen sowie f\u00fcr Arzneimittel, die einer zus\u00e4tzlichen \u00dcberwachung unterliegen, gem\u00e4\u00df \u00a7 11 Absatz 1b und \u00a7 11a Absatz 1 Satz 9 des Arzneimittelgesetzes (AMG), vom 3. Juli 2013. www.bfarm.de\/SharedDocs\/Bekanntmachungen\/DE\/Pharmakovigilanz\/bm-phvig-20130807-standardsaetze.pdf?__blob=publicationFile&v=6 (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref27","doi-asserted-by":"crossref","unstructured":"Inch J, Watson MC, Anakwe-Umeh S: Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review. Drug Saf 2012; 35: 807\u201318","DOI":"10.1007\/BF03261977"},{"key":"10.3238\/arztebl.2018.0393_ref28","unstructured":"European Medicines Agency: Annual Report 2016. www.ema.europa.eu\/docs\/en_GB\/document_library\/Annual_report\/2017\/05\/WC500227334.pdf (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref29","doi-asserted-by":"crossref","unstructured":"Thiessard F, Roux E, Miremont-Salame G, et al.: Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986\u20132001). Drug Saf 2005; 28: 731\u201340","DOI":"10.2165\/00002018-200528080-00007"},{"key":"10.3238\/arztebl.2018.0393_ref30","doi-asserted-by":"crossref","unstructured":"Ozcan G, Aykac E, Kasap Y, Nemutlu NT, Sen E, Aydinkarahaliloglu ND: Adverse drug reaction reporting pattern in Turkey: analysis of the national database in the context of the first pharmacovigilance legislation. Drugs Real World Outcomes 2016; 3: 33\u201343","DOI":"10.1007\/s40801-015-0054-1"},{"key":"10.3238\/arztebl.2018.0393_ref31","doi-asserted-by":"crossref","unstructured":"Aagaard L, Strandell J, Melskens L, Petersen PS, Holme Hansen E: Global patterns of adverse drug reactions over a decade. Drug Saf 2012; 35: 1171\u201382","DOI":"10.1007\/BF03262002"},{"key":"10.3238\/arztebl.2018.0393_ref32","doi-asserted-by":"crossref","unstructured":"Alhawassi TM, Krass I, Bajorek BV, Pont LG: A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging 2014; 9: 2079\u201386","DOI":"10.2147\/CIA.S71178"},{"key":"10.3238\/arztebl.2018.0393_ref33","doi-asserted-by":"crossref","unstructured":"Knopf H, Grams D: Arzneimittelanwendung von Erwachsenen in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsbl 2013; 56: 868\u201377","DOI":"10.1007\/s00103-013-1667-8"},{"key":"10.3238\/arztebl.2018.0393_ref34","doi-asserted-by":"crossref","unstructured":"Telschow C, Schr\u00f6der M: Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J (eds.): Arzneiverordnungs-Report 2017. Berlin, Heidelberg: Springer 2017; 783\u2013792.","DOI":"10.1007\/978-3-662-54630-7_49"},{"key":"10.3238\/arztebl.2018.0393_ref35","doi-asserted-by":"crossref","unstructured":"Klotz U: Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67\u201376","DOI":"10.1080\/03602530902722679"},{"key":"10.3238\/arztebl.2018.0393_ref36","doi-asserted-by":"crossref","unstructured":"H\u00e4mmerlein A, Derendorf H, Lowenthal DT: Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet 1998; 35: 49\u201364","DOI":"10.2165\/00003088-199835010-00004"},{"key":"10.3238\/arztebl.2018.0393_ref37","doi-asserted-by":"crossref","unstructured":"Glaeske G, Gerdau-Heitmann C, H\u00f6fel F, Schicktanz C: \u201eGender-specific drug prescription in Germany\u201c results from prescription analysis. In: Regitz-Zagrosek V (ed.): Sex and gender differences in pharmacology. Berlin, Heidelberg: Springer 2012; 149\u201367","DOI":"10.1007\/978-3-642-30726-3_8"},{"key":"10.3238\/arztebl.2018.0393_ref38","doi-asserted-by":"crossref","unstructured":"Zopf Y, Rabe C, Neubert A, et al.: Gender-based differences in drug prescription: relation to adverse drug reactions. Pharmacology 2009; 84: 333\u20139","DOI":"10.1159\/000248311"},{"key":"10.3238\/arztebl.2018.0393_ref39","unstructured":"L\u00fctkeherm\u00f6lle W, Paeschke N: Einf\u00fchrung in die Grundlagen der Pharmakovigilanz (Teil I) \u2013 Verdachtsf\u00e4lle von unerw\u00fcnschten Arzneimittelwirkungen. Bulletin zur Arzneimittelsicherheit 2010; 1: 14\u20137."},{"key":"10.3238\/arztebl.2018.0393_ref40","doi-asserted-by":"crossref","unstructured":"Hazell L, Shakir SA: Under-reporting of adverse drug reactions. Drug Saf 2006; 29: 385\u201396","DOI":"10.2165\/00002018-200629050-00003"},{"key":"10.3238\/arztebl.2018.0393_ref41","doi-asserted-by":"crossref","unstructured":"Hasford J, Goettler M, Munter KH, M\u00fcller-Oerlinghausen B: Physicians\u2019 knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 945\u201350","DOI":"10.1016\/S0895-4356(02)00450-X"},{"key":"10.3238\/arztebl.2018.0393_ref42","unstructured":"BfArM: Dimethylfumarathaltige Arzneimittel und progressive multifokale Leukencephalopathie (PML). Stand: 7. April 2015. www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RI\/2015\/RI-dimethylfumarat.html (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref43","unstructured":"BfArM: Kava-Kava, Widerruf der Zulassung. Stand: 31. August 2015. www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/g-l\/kavakava3.html (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref44","unstructured":"BfArM: Bufexamac-haltige Arzneimittel: Kontaktallergische Reaktionen. Feststellungsbescheid. Stand 5. Mai 2010. www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/a-f\/bufexamac.html (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref45","unstructured":"BfArM: Glossar: over the counter OTC. www.bfarm.de\/SharedDocs\/Glossareintraege\/DE\/O\/OTC.html (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref46","unstructured":"MedDRA: Standardised MedDRA queries. www.meddra.org\/standardised-meddra-queries (last accessed on 17 April 2018)."},{"key":"10.3238\/arztebl.2018.0393_ref47","unstructured":"Farzan J: Neue Pharmakovigilanz-Gesetzgebung in der EU. Bulletin zur Arzneimittelsicherheit 2011; 3: 14\u20137."},{"key":"10.3238\/arztebl.2018.0393_ref48","unstructured":"BfArM: Glossar: Schwarzes Dreieck. www.bfarm.de\/SharedDocs\/Glossareintraege\/DE\/S\/Schwarzes_Dreieck.html (last accessed on 17 April 2018)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:44:24Z","timestamp":1638798264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":48,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0393","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]}}}